Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
ADSTEM Inj.
BIOLOGICAL
3 trials
Sponsors
EHL Bio Co., Ltd.
Conditions
Atopic Dermatitis
Phase 2
Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis
Active, not recruiting
NCT04137562
EHL Bio Co., Ltd.
Atopic Dermatitis
Start: 2019-12-11
End: 2027-10-31
Updated: 2026-06-22
Phase 3
Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis
Not yet recruiting
NCT07377838
EHL Bio Co., Ltd.
Atopic Dermatitis
Start: 2026-06-01
End: 2029-12-01
Target: 286
Updated: 2026-02-12
Unknown Phase
Safety of ADSTEM Injection in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis
Completed
NCT03252340
EHL Bio Co., Ltd.
Atopic Dermatitis
Start: 2017-09-19
End: 2022-09-27
Updated: 2023-02-15
Related Papers
Efficacy and safety of autologous adipose-derived stem cells in subjects with moderate to severe atopic dermatitis: a multicenter, randomized, single-blind, placebo-controlled, phase 2 trial.
2025-12-02